About: Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $4.54 (+0.89%)
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
27 Apr, 9:31 am GMT+0
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Market cap
N/A
NYSE rank
N/A
Sector Rank
N/A
Delayed
27 Apr, 9:31 am GMT+0
LRMR Market Signals